Investigational drug · Phase 2
RLY-2608
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "RLY-2608"
First trial start
2025
Jun 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RLY-2608", any sponsor or status.
Conditions studied
As listed on its trial records.
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Lymphatic Malformations
- Vascular Malformations
- PIK3CA Mutation
- CLOVES Syndrome
- Klippel Trenaunay Syndrome
- Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
- Vascular Anomalies
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "RLY-2608" as an intervention, largest first.
Relay Therapeutics, Inc.Industry
NCT05216432 · 930 participants (planned) · Start Dec 8, 2021 · Primary completion Apr 30, 2027
Drug: RLY-2608; Fulvestrant and 5 more · For: PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer and 4 more
Sites: Tucson, Arizona; San Diego, California; Denver, Colorado · 37 sites in all
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPivotal-lookingRecruiting
Relay Therapeutics, Inc.Industry
NCT06982521 · 540 participants (planned) · Start Aug 26, 2025 · Primary completion Apr 30, 2028
Drug: Zovegalisib; Capivasertib and 1 more · For: PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor and 3 more
Sites: Gilbert, Arizona; Beverly Hills, California; Duarte, California · 254 sites in all
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)Pivotal-lookingRecruiting
Relay Therapeutics, Inc.Industry
NCT06789913 · 277 participants (planned) · Start Jun 13, 2025 · Primary completion Jul 2031
Drug: RLY-2608; Placebo · For: PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Malformations and 5 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 49 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Zovegalisib for PIK3CA-driven vascular and lymphatic malformations: a drug evaluation.
Seront E, Van Damme A, Coulie J, et al. · Expert Opin Investig Drugs 2026
- Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478.
Liu X, Chen Y, Li G, et al. · Acta Pharm Sin B 2026
- Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.
Liu X, Chen Y, Han W, et al. · Annu Rev Pharmacol Toxicol 2026
- Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Tyrakis PA, Kampjut D, Steele GF, et al. · Br J Cancer 2025
- In Silico Discovery of a Novel Potential Allosteric PI3Kα Inhibitor Incorporating 3-(2-Chloro-5-fluorophenyl)isoindolin-1-one to Target Head and Neck Squamous Cell Carcinoma.
Jia W, Cheng X · Biology (Basel) 2025
- mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs.
Liu Y, Zhang W, Jang H, et al. · J Chem Inf Model 2025
Also in development for PIK3CA-Related Overgrowth Spectrum (PROS)
- CYH33Phase 22 trials
Haihe Biopharma Co., Ltd. · PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM), Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.